Patients with the GGAGTC/GGAGTC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC/del or del/del. Other genetic and clinical factors may also influence a patient's risk for toxicity.